Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 18/20 | 0.62 |
| ▸ | USP7 | Q93009 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501320 | 0.91 | SMN1; SMN2 (0.62) | USP14USP7SMN1; SMN2HPGD | |
| SCHEMBL6923922 | 0.88 | SMN1; SMN2 (0.52) | USP14USP7SMN1; SMN2HPGD | |
| SCHEMBL14708800 | 0.86 | SMN1; SMN2 (0.50) | USP14USP7SMN1; SMN2HPGD | |
| SCHEMBL5365241 | 0.83 | CNR1 (0.68) | USP14USP7 | |
| SCHEMBL23524525 | 0.78 | USP14 (0.69) | USP14USP7SMN1; SMN2 | |
| SCHEMBL6922465 | 0.77 | USP14 (1.00) | USP14USP7SMN1; SMN2HPGD | |
| SCHEMBL17949751 | 0.77 | USP14 (1.00) | USP14USP7SMN1; SMN2HPGD | |
| SCHEMBL23524536 | 0.76 | USP14 (0.66) | USP14USP7SMN1; SMN2HPGD | |
| SCHEMBL6921679 | 0.75 | SMN1; SMN2 (1.00) | USP14USP7SMN1; SMN2HPGD | |
| SCHEMBL23524504 | 0.75 | USP14 (0.78) | USP14USP7SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-07-16 | — | — | US | disclosed |
| EP-2528911-B1 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | HARVARD COLLEGE (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | THE ASSAY DEPOT, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | THE ASSAY DEPOT, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20140275169-A1 | Combination Therapies for Enhancing Protein Degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275169-A1 | Combination Therapies for Enhancing Protein Degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014116228-A1 | USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011094545-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PSMG3, PSME3, PSMB11 | USP14 12/4885USP7 45/4885SMN1; SMN2 307/4885 |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSMB11, PSME3 | USP14 6/4885USP7 43/4885SMN1; SMN2 307/4885 |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSME3, PSMB11 | USP14 12/4885USP7 45/4885SMN1; SMN2 307/4885 |
| US-20140275169-A1 | Combination Therapies for Enhancing Protein Degradation | HSPA2, HSPBP1, HSPH1 | USP14 10/4885USP7 72/4885SMN1; SMN2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.